Nanostructural changes in bone quality in a mouse model of chronic kidney disease and treatment with calcitonin

Area of Science:

• Nephrology
• Orthopedics
• Biomaterials Science

Background:

• Chronic kidney disease (CKD) causes mineral imbalances, leading to bone turnover issues and cortical bone loss.
• Synthetic salmon calcitonin is FDA-approved for bone fragility in conditions like osteoporosis, reducing fracture risk.

Purpose of the Study:

• To investigate the effects of synthetic salmon calcitonin on cortical bone quality in a mouse model of CKD.
• To assess calcitonin's impact on bone nanostructure and composition under CKD conditions.

Main Methods:

• Utilized an in vivo mouse model of CKD, administering calcitonin (50 IU/kg/day, 5x/week for 5 weeks).
• Employed MicroCT for evaluating bone quantity (porosity, thickness, area) and structural geometry.
• Applied Small and Wide-Angle X-ray Scattering (SAXS/WAXS) for mineral-collagen-water nanostructure analysis.
• Used Thermogravimetric Analysis (TgA) to quantify mineral, collagen, and water content (wt.%).

Main Results:

• CKD significantly affected bone porosity, thickness, and geometry, but calcitonin treatment showed no significant impact on these parameters.
• CKD decreased collagen spacing, increased mineral weight fractions, and reduced loosely bound water.
• Calcitonin treatment increased collagen weight percent but did not alter mineral dimensions, D-periodicity, or other bone quality metrics.

Conclusions:

• The tested calcitonin regimen did not reverse CKD-induced cortical bone structural changes in mice.
• CKD significantly alters bone nanostructure and composition, impacting collagen spacing and water content.
• Further research is needed to explore calcitonin's efficacy and optimal dosing for CKD-related bone disease.